131 related articles for article (PubMed ID: 1823903)
1. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH.
Naylor PH; Sztein MB; Wada S; Maurer S; Holterman D; Kirkley JE; Naylor CW; Zook BC; Hitzelberg RA; Gibbs CJ
Int J Immunopharmacol; 1991; 13 Suppl 1():117-27. PubMed ID: 1823903
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
Sarin PS; Mora CA; Naylor PH; Markham R; Schwartz D; Kahn J; Heseltine P; Gazzard B; Youle M; Rios A
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):401-7. PubMed ID: 7580834
[TBL] [Abstract][Full Text] [Related]
3. Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.
Zimmerman DH; Ulrich JT; Wright C; Lloyd JP; Winship MD; Sarin PS
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):741-9. PubMed ID: 9643374
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
5. Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.
Zimmerman DH; Lloyd JP; Heisey D; Winship MD; Siwek M; Talor E; Sarin PS
Vaccine; 2001 Sep; 19(32):4750-9. PubMed ID: 11535326
[TBL] [Abstract][Full Text] [Related]
6. Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine.
Pisarev VM; Parajuli P; Mosley RL; Sublet J; Kelsey L; Sarin PS; Zimmerman DH; Winship MD; Talmadge JE
Int J Immunopharmacol; 2000 Nov; 22(11):865-76. PubMed ID: 11090695
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects.
Kahn JO; Stites DP; Scillian J; Murcar N; Stryker R; Volberding PA; Naylor PH; Goldstein AL; Sarin PS; Simmon VF
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1321-5. PubMed ID: 1466950
[TBL] [Abstract][Full Text] [Related]
8. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
Iaria ML; Fiorentini S; Focà E; Zicari S; Giagulli C; Caccuri F; Francisci D; Di Perri G; Castelli F; Baldelli F; Caruso A
Vaccine; 2014 Feb; 32(9):1072-8. PubMed ID: 24456624
[TBL] [Abstract][Full Text] [Related]
9. HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.
Achour A; Picard O; Zagury D; Sarin PS; Gallo RC; Naylor PH; Goldstein AL
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7045-9. PubMed ID: 1698289
[TBL] [Abstract][Full Text] [Related]
10. Flt3 ligand and conjugation to IL-1beta peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine.
Pisarev VM; Parajuli P; Mosley RL; Chavez J; Zimmerman D; Winship D; Talmadge JE
Vaccine; 2002 May; 20(17-18):2358-68. PubMed ID: 12009292
[TBL] [Abstract][Full Text] [Related]
11. Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice.
Sarin PS; Talmadge JE; Heseltine P; Murcar N; Gendelman HE; Coleman R; Kelsey L; Beckner S; Winship D; Kahn J
Vaccine; 1999 Jan; 17(1):64-71. PubMed ID: 10078609
[TBL] [Abstract][Full Text] [Related]
12. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection.
Jiang JD; Chu FN; Naylor PH; Kirkley JE; Mandeli J; Wallace JI; Sarin PS; Goldstein AL; Holland JF; Bekesi JG
J Acquir Immune Defic Syndr (1988); 1992; 5(4):382-90. PubMed ID: 1372353
[TBL] [Abstract][Full Text] [Related]
13. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
14. The multi-epitope polypeptide approach in HIV-1 vaccine development.
Cano CA
Genet Anal; 1999 Nov; 15(3-5):149-53. PubMed ID: 10596755
[TBL] [Abstract][Full Text] [Related]
15. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
[TBL] [Abstract][Full Text] [Related]
16. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30.
Naylor PH; Naylor CW; Badamchian M; Wada S; Goldstein AL; Wang SS; Sun DK; Thornton AH; Sarin PS
Proc Natl Acad Sci U S A; 1987 May; 84(9):2951-5. PubMed ID: 2437588
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope.
Focà E; Iaria ML; Caccuri F; Fiorentini S; Motta D; Giagulli C; Castelli F; Caruso A
HIV Clin Trials; 2015 Aug; 16(4):157-62. PubMed ID: 26057863
[TBL] [Abstract][Full Text] [Related]
19. Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
Ferrari G; Neal W; Ottinger J; Jones AM; Edwards BH; Goepfert P; Betts MR; Koup RA; Buchbinder S; McElrath MJ; Tartaglia J; Weinhold KJ
J Immunol; 2004 Aug; 173(3):2126-33. PubMed ID: 15265949
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
